Year: 2025

With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants and antibiotics, as well as steroid hormones and vitamin D metabolites. The comprehensive menu brings the sensitivity and specificity of gold-standard testing into routine labs for a wide range of the most frequently tested targets. The fully automated solution replaces labour-intensive manual workflows, reducing turnaround times and supporting faster, standardised, high-quality care.Basel, 11 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche’s in-vitro diagnostics (IVD)...

OSLO, Norway (11 December 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a streamer 4D contract in the Campos basin, offshore Brazil. A Ramform vessel is scheduled to mobilize for the survey in the second half of 2026, with the contract expected to last approximately 75 days.   Kristian Johansen, CEO of TGS, commented, “We are very pleased to secure this 4D streamer contract for an independent energy company in Brazil. By leveraging our purpose-built Ramform designed vessel, equipped with our proprietary GeoStreamer technology, we will deliver high-quality data to optimize their production, while maintaining industry-leading acquisition efficiency.” For more information, visit TGS.com or contact: Bård StenbergVP IR & Business intelligence Mobile: +47 992 45 235investor@tgs.com About...

Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China’s irradiation processing industry to a new stage of high-quality development. The Jianxing center in East China will be the first CGI center to install X-ray technology. It will provide expanded irradiation capacity to this medical device centralized area as well as abundant capacity to nurture related industries where high standard irradiation service is needed such as biological and traditional...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorderParis, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. These approvals mark another step in Sanofi’s long-term commitment to China, reinforcing the company’s ambition to bring transformative medicines across diverse disease areas. With Qfitlia and Cablivi,...

Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) —BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027 Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and BV100 selection by ADVANCE-ID for upcoming Phase 2b, mostly financed by Wellcome Strong news flow expected in 2026 including: 1st DSMB review for BV100 Phase 3, Interim data read-out for BV100 Phase 2b and Read-out of Phase 2 alpibectir in pulmonary...

Inside / regulated information Aalst, Belgium, December 11, 2025 – Ontex Group NV, a leading international developer and producer of personal care products, revises its full year expectations for revenue growth downward, following  a of its baby care sales in October and November, as a result of weaker-than-expected consumer demand. This revision also impacts Ontex’s adjusted EBITDA, free cash flow and leverage ratio expectations. The consumption of retailer brands dropped sequentially in the fourth quarter, both in Europe and North America, as consumer demand weakened further, and as promotional activity by A-brands remains intense. Based on the lower-than-expected sales volumes, Ontex now anticipates a high-single digit like-for-like revenue drop in the fourth quarter compared to the fourth quarter of 2024, whereas a largely stable performance...

Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseasesCollaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial milestone payments, for a potential total consideration of up to USD ~2.5 billion, with the majority representing commercial milestones, plus tiered royaltiesCopenhagen,...

Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture that uses Artificial Intelligence (AI) to accelerate antibiotic discovery and development. Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules with antibacterial properties that meet a pre-defined target product profile, which considers both unmet medical needs and the features relevant for potential commercial success of a future product. Following identification of molecules matching this profile, Basilea will assume responsibility for subsequent development and Phare Bio will be eligible...

Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic healthZealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026 New research site in Boston to combine our +25-year peptide heritage with AI-driven drug discovery, advanced automation, and next-generation molecule creationCopenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight...

Inside / regulated information Aalst, Belgium, December 11, 2025 – The Board of Directors of Ontex (Euronext: ONTEX) has decided to appoint Mr. Laurent Nielly as Chief Executive Officer, effective as from the end of Mr. Gustavo Calvo Paz’s mandate as Chief Executive Officer at Ontex’s next annual shareholders’ meeting, on May 5, 2026. Since 2021, Mr. Nielly has been President of Ontex’s Europe Division, leading our retailer brands and healthcare business across Europe.  Prior to that, Mr. Nielly led Ontex’s business in Brazil.  Laurent Nielly brings more than 25 years of experience earned in Europe, the US and Latin America and across companies such as P&G, McKinsey & Company, PepsiCo and Coty. He started his professional career in finance and strategy, and developed expertise in innovation and commercial excellence in addition...